← All trials
NCT02433509
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2015
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- May 5, 2015
- Last posted
- Nov 23, 2021
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Medical UniversityLead sponsor
- Tzu Chi UniversityCollaborator
- Tzu Chi UniversityOverall official - principal investigator
- Tzu Chi UniversityReponsible party - principal investigator
- StemCyte, Inc.Collaborator
- University of South FloridaCollaborator
- Tzu Chi UniversitySponsor investigator
- Tzu Chi UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.